Collaboration. Acceleration. Results.
Myelin Repair Foundation Home Page

President’s Letter:

Photo of Scott Johnson

Scott Johnson, Myelin Repair Foundation President, CEO and Founder … waiting for a cure since 1976

Dear Friends and Supporters of MRF,

As our name clearly states MRF has always had a focus only on accelerating myelin repair treatments to MS patients. Because of our past successes, with input from a broad array of experts, in 2017 we narrowed our attention even more – to helping identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials.

Biomarkers are difficult and expensive to identify and ideally require collaboration to combine the creativity of academic researchers, the expertise resident only in pharmaceutical companies, human samples from government run biobanks, and access to MS patients via clinicians. Organizing and driving this type of endeavor perfectly fits MRF’s track record and unique capabilities.

To guide this effort scientifically we recruited Susan Goelz, Ph.D. Susan is a pharmaceutical industry veteran with 25 years at Biogen and several years at Elan Pharmaceuticals. While at Biogen she helped develop and gain regulatory approval of Avonex, Tysabri, and Tecfidera for use by MS patients.

Since about 2000, finding areas of collaboration between the biotech industry and academic groups has also been a major area of her focus. She has initiated and managed more than 100 collaborations in these areas. Dr. Goelz is an author on more than 60 publications, dozens of posters and lectures presented at international meetings; and is named as an inventor on several patents.

Dr. Goelz brings 30 years of experience and a wealth of relationships with both senior pharma industry scientific leaders and top academic scientists. She maintains and grows her network via constant interactions at meetings such as ACTRIMS and ECTRIMS as well as one on one meetings.

With input from MRF’s stellar advisors, she formulates critical biomarker-related questions and then determines which scientists from around the world are best equipped to conduct an experiment to obtain a scientific answer. MRF then works with that scientist or team of scientists to complete the experiment and scientific analysis. This process is very different and much more “hands on” than the typical request for proposals, peer review, award grant and wait for a paper to be published approach, used by other medical research non-profits.

Thank you for your support. I look forward to providing on-going updates as we make progress.



Focus on Biomarkers

The Myelin Repair Foundation is identifying biomarkers to help accelerate myelin repair treatments. Learn more about the importance of biomarkers and the role they play in getting treatments to patients.